CARBOPLATIN-EBEWE

DRUG2 trials

Sponsors

Revolution Medicines Inc.

Conditions

Lung Cancer

Phase 1

Study of RMC-6291, With or Without RMC-6236, in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A

RecruitingCTIS2023-509571-16-00

Revolution Medicines Inc.Lung Cancer

Start: 2024-07-17Target: 162Updated: 2025-12-17

A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B

RecruitingCTIS2023-509572-42-00

Revolution Medicines Inc.Lung Cancer

Start: 2024-07-17Target: 180Updated: 2026-01-13